within Pharmacolibrary.Drugs.ATC.J;

model J05AX31
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.883333333333333e-06,
    adminDuration  = 600,
    adminMass      = 927 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0061600000000000005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00684,
    k12             = 0.204,
    k21             = 0.204
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX31</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lenacapavir is a first-in-class long-acting capsid inhibitor used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are heavily treatment-experienced. It works by inhibiting the HIV-1 capsid protein, thereby disrupting multiple steps of the viral life cycle. Lenacapavir is approved for use in the United States and European Union.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, after subcutaneous administration.</p><h4>References</h4><ol><li><p>Hitchcock, AM, et al., &amp; Sidman, EF (2024). Lenacapavir: A novel injectable HIV-1 capsid inhibitor. <i>International journal of antimicrobial agents</i> 63(1) 107009–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2023.107009&quot;>10.1016/j.ijantimicag.2023.107009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37844807/&quot;>https://pubmed.ncbi.nlm.nih.gov/37844807</a></p></li><li><p>Jogiraju, V, et al., &amp; Singh, R (2025). Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. <i>Lancet (London, England)</i> 405(10485) 1147–1154. DOI:<a href=&quot;https://doi.org/10.1016/S0140-6736(25)00405-2&quot;>10.1016/S0140-6736(25)00405-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40086460/&quot;>https://pubmed.ncbi.nlm.nih.gov/40086460</a></p></li><li><p>Ogbuagu, OE, et al., &amp; Molina, JM (2025). Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. <i>AIDS (London, England)</i> 39(6) 639–648. DOI:<a href=&quot;https://doi.org/10.1097/QAD.0000000000004142&quot;>10.1097/QAD.0000000000004142</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39912752/&quot;>https://pubmed.ncbi.nlm.nih.gov/39912752</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX31;
